NIKKEI 225
27,515.95 -90.51 (-0.33%) HANG SENG
21,356.79 +73.27 (+0.34%) CRUDE OIL
78.42 -0.05 (-0.06%) GOLD FUTURES
1,890.70 0.00 (0.00%) DOW
33,949.01 -207.68 (-0.61%) BTC-GBP
18,659.03 -691.81 (-3.58%)
Alkuri Global Acquisition Corp. (KURIU)
| Previous close | 10.02 |
| Open | 10.23 |
| Bid | 9.48 x 1000 |
| Ask | 0.00 x 1100 |
| Day's range | 9.48 - 10.23 |
| 52-week range | 9.48 - 11.49 |
| Volume | |
| Avg. volume | 20,282 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Babylon Delivers Strong 2022 Results, Beating Expectations
AUSTIN, Texas & LONDON, January 12, 2023--Babylon Holdings Limited (NYSE: BBLN) ("Babylon" or the "Company") today confirmed that its revenue for the year ended December 31, 2022 is expected to exceed $1.05 billion on both a U.S. GAAP and International Financial Reporting Standards (IFRS) basis, including revenue from the IPA business in California. Babylon also expects to beat its previous IFRS Adjusted EBITDA guidance of $(270) million or less for 2022. These financial results are preliminary,
- Business Wire
Babylon Announces Additional Details on its Upcoming 1-for-25 Reverse Share Split
AUSTIN, Texas & LONDON, December 08, 2022--Babylon (NYSE: BBLN) ("Babylon'') today announced additional details concerning the previously announced 1-for-25 reverse share split (the "Reverse Share Split") of its Class A ordinary shares, par value $0.0000422573245084686 per share (the "Class A Ordinary Shares"), which will become effective on December 15, 2022 (the "Effective Date"). These shares are expected to begin trading on a split-adjusted basis at market open on December 16, 2022.
- Business Wire
Babyl & Novo Nordisk partner to provide an innovative approach to diabetes awareness and care in Rwanda
AUSTIN, Texas & KIGALI, Rwanda & LONDON, December 01, 2022--Babyl, a subsidiary of Babylon (NYSE: BBLN), and Novo Nordisk announced today that they have entered an innovative partnership to contribute to the expansion of diabetes awareness and care in Rwanda. Drawing on Novo Nordisk’s expertise and mission to drive change to defeat diabetes and Babyl’s existing infrastructure and experience in delivering digital health services at scale in Rwanda, this new joint initiative aims to improve awaren
